Samchundang Pharm penalized for disclosure lapse, raising concerns for biotech trust

 
Samchundang Pharm, a KOSDAQ-listed company, has been designated an unfaithful disclosure firm. The Korea Exchange’s KOSDAQ Market Division imposed five penalty points, citing a failure to carry out fair disclosure of “forecasts or predictions regarding business performance.” Its cumulative penalty points over the past year now total five. The exchange finalized the sanction after a notice last month and a review by a disclosure committee that included outside experts.
 
While the case appears to be a single company’s disclosure violation, it underscores a broader issue for the pharmaceutical and biotech sector, where disclosures are not a routine formality. Information such as research and development results, clinical progress, the possibility of technology exports and sales outlooks can directly affect corporate value and share prices. Because investors cannot easily evaluate products themselves, they rely on disclosures to judge a company’s prospects; when disclosures falter, the market’s basis for judgment weakens.
 
Biotech is also an industry where expectations and uncertainty coexist, with future earnings that have not yet materialized reflected in current valuations. That structure demands stricter information sharing. Even small wording choices, schedule changes or shifts in the tone of guidance can influence investment decisions. In that context, neglecting fair-disclosure obligations is likely to be seen as more than a simple mistake.
 
The concern grows when such cases recur. The damage does not stop with one company, the editorial said, warning that Korea’s broader biotech sector can come under suspicion that statements run ahead of disclosures. Overseas investors may apply a discount to Korean biotech firms, and retail investors may lose confidence in the sector, hurting even stronger companies.
 
The five-point penalty is a warning, but sanctions alone are not enough, it said. Companies need internal controls that place disclosure under top management responsibility, with R&D, investor relations, and legal and finance functions working to review material information promptly and deliver it to the market under consistent standards.
 
Regulators, it added, should not rely only on after-the-fact punishment. It called for tighter disclosure guidelines reflecting the characteristics of the pharmaceutical and biotech industries and for clearer standards on what predictive disclosures may include and what responsibilities follow. The goal, it said, should be a system that prevents violations born of confusion while holding firms strictly accountable when rules are knowingly broken.
 
As Korea’s biotech industry pushes into global markets, technology alone is not enough, the editorial said. Capital-market trust must keep pace, and a culture of stating numbers and facts accurately is essential for laboratory achievements to be recognized by the market. The Samchundang Pharm case, it said, is a reminder to return to those basics.